Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/2/17 → 06/25/22 |
Funding
- Boehringer Ingelheim Pharmaceutical: $50,626.80
IQVIA RDS: A Phase III Randomized, Double-Blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients with Chronic Heart Failure with Preserved Ejection Fraction (HFpEF)
- Skopicki, Hal (PI)
- Bloom, Michelle (CoPI)
- Borriello, Caitlin (CoPI)
- Pilato, Lauren (CoPI)
Project: Research